Dr Greg Fegan
Head, Clinical Trials Support Group (CTSG)
Greg Fegan joined MORU in May 2022 as Head of the Clinical Trials Support Group (CTSG). The CTSG team works with investigators to support MORU’s mission of finding practical solutions to major tropical disease problems. Prior to MORU Greg was Professor of Clinical Trials and Director of the Swansea Trials Unit (STU) at Swansea University’s Medical School from December 2015 and retains an honorary professorship there.
Greg worked at the KEMRI-Wellcome Trust Research Programme for 12 years from 2003. For the first six years he was the Unit Statistician and affiliated with the London School of Hygiene & Tropical Medicine (LSHTM). For the latter six years, he was Head of Statistics employed through Oxford’s Centre for Tropical Medicine. Other posts held included roles with the Louisiana Office of Public Health, MRC Laboratories - The Gambia, the Demographic and Health Surveys, and the Centre for Population Studies at LSHTM. Greg has also undertaken consultancy work for various organizations including CDC, WHO and UNICEF.
Greg holds a PhD in Epidemiology from Tulane University’s School of Public Health and Tropical Medicine plus an MSc in Information Systems Engineering from South Bank Polytechnic (now University). Greg has contributed to 130+ scientific articles including a number in leading scientific journals. Specific key contributions include Mramba L et al BMJ (2017), Olotu A et al N Engl J Med (2016 & 2014), Warimwe G et al. Sci Transl Med. (2012), Fegan G et al Lancet (2007), and Alonso P et al Lancet (1991)
Hughes abdominal closure versus standard mass closure to reduce incisional hernias following surgery for colorectal cancer: the HART RCT.
O'Connell S. et al, (2022), Health technology assessment (Winchester, England), 26, 1 - 100
Sunproofed study protocol: A mixed-methods scoping study of sun safety policies in primary schools in Wales.
Peconi J. et al, (2022), PloS one, 17
Dementia Early-Stage Cognitive Aids New Trial (DESCANT) of memory aids and guidance for people with dementia: randomised controlled trial.
Clarkson P. et al, (2021), Journal of neurology, neurosurgery, and psychiatry
Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol.
Gregory JW. et al, (2021), BMJ open, 11
Randomised feasibility study of prehospital recognition and antibiotics for emergency patients with sepsis (PhRASe).
Jones J. et al, (2021), Scientific reports, 11